Back to search

Article

Immune response to an adjuvanted recombinant zoster vaccine in Japanese patients with rheumatoid arthritis receiving upadacitinib (End Zoster-J study)

2024-09-26

Abstract excerpt

<title>Abstract</title><p>Background Janus kinase (JAK) inhibitors have emerged as a new class of disease-modifying anti-rheumatic drugs in the treatment of rheumatoid arthritis (RA). However, herpes zoster is one of the common adverse events of JAK inhibitors, including upadacitinib, which is especially high in Japanese patients with RA compared to those from Western countries. Recombinant zoster vaccine (Shingri...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
91f46439-caed-5a4e-b810-e86fec4da2b0
DOI
10.21203/rs.3.rs-5097927/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Immune response to an adjuvanted recombinant zoster vaccine in Japanese patients with rheumatoid arthritis receiving upadacitinib (End Zoster-J study)DOI 10.21203/rs.3.rs-5097927/v1
Real-world Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in ≥50-year-old Adults With Autoimmune DiseasesSemantic proximity
Safety of Coronavac and ChAdOx1 Vaccines Against SARS-CoV-2 in Patients with Rheumatoid Arthritis Data from the Brazilian Multicentric Study SaferSemantic proximity
New onset rheumatoid arthritis with refractory hyper-eosinophilia associated with inactivated COVID-19 vaccineSemantic proximity
Increased Risk of Herpes Zoster in Rheumatoid Arthritis Is Not Only Due to Jak Inhibitors: Study of 392 Patients from a Single University CenterSemantic proximity
Recombinant Zoster Vaccine Uptake and Risk of Flares Among Older Adults With Immune‐Mediated Inflammatory Diseases in the USSemantic proximity
Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR’HIV): a multicenter, international, non-randomized clinical trial study protocolSemantic proximity
Identification and characterization of CD4+ T cell epitopes after Shingrix vaccinationSemantic proximity
Efficacy and side effects of the Herpes Zoster vaccine in immunocompromised individuals – a systematic reviewSemantic proximity
Safety and reactogenicity of the recombinant zoster vaccine after allogeneic hematopoietic cell transplantationSemantic proximity
Potent and long-lasting humoral and cellular immunity against varicella zoster virus induced by mRNA-LNP vaccineSemantic proximity
Administering Shingles Vaccine Prior to Initiation of Biologics TherapySemantic proximity
Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial.Semantic proximity
Select a neighboring publication to make it the new centre.